Oral Testosterone Undecanoate Formulation with Dynamic Dose Titration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current testosterone replacement therapies for treating testosterone deficiency in men suffer from poor compliance and unsatisfactory treatment outcomes, with many patients not adhering to long-term therapy due to inefficiencies in maintaining optimal serum testosterone levels.
Innovation Solution
An oral pharmaceutical composition of testosterone undecanoate solubilized in a carrier comprising lipophilic and hydrophilic surfactants, with a titration method to adjust doses based on serum testosterone concentration, ensuring levels remain between 425 ng/dL and 970 ng/dL to optimize treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If testosterone replacement therapy is administered to treat testosterone deficiency, then serum testosterone levels increase, but patient compliance deteriorates due to poor adherence to long-term therapy
Solution Approach 1:
The patent implements dynamic dose adjustment based on measured serum testosterone levels. The method involves initial dosing followed by monitoring of testosterone concentrations and subsequent modification of the dose to achieve and maintain target levels (e.g., 300-1000 ng/dL). This dynamic approach allows treatment to adapt to individual patient responses, improving both efficacy and compliance by preventing side effects from excessive dosing while ensuring adequate hormone replacement.
Solution Approach 2:
The patent incorporates feedback mechanisms through regular measurement of serum testosterone levels to guide dose adjustment decisions. The method specifies monitoring testosterone concentrations at defined intervals (e.g., 4-8 weeks after initiation or dose change) and using these measurements to determine whether to increase, decrease, or maintain the current dose. This closed-loop feedback system ensures optimal treatment outcomes while enhancing patient compliance through personalized dosing.
2Ease of operation
If a fixed dose of testosterone replacement therapy is administered, then treatment simplicity is maintained, but individual patient needs are not met resulting in suboptimal serum testosterone levels
Solution Approach 1:
The patent transitions from static fixed dosing to dynamic dose adjustment based on individual patient responses. The method specifies starting with an initial dose (e.g., 20-40 mg intramuscularly or equivalent oral/topical dose) and then adjusting based on measured testosterone levels. This allows the treatment to evolve from simple to personalized, maintaining ease of administration while improving efficacy through customization.
Solution Approach 2:
The patent modifies the dosage parameter based on measured serum testosterone levels and clinical response. The method provides specific guidance for dose adjustment: increase if levels are below target range, decrease if above target range or side effects occur, and maintain if optimal levels are achieved. This parameter change approach allows flexible optimization of treatment efficacy while preserving treatment simplicity through standardized adjustment protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively maintains serum testosterone within a therapeutic range, improving treatment compliance and efficacy by allowing for dose adjustments to meet individual patient needs, thereby addressing the limitations of existing therapies.
Implementation Method 1
an oral pharmaceutical composition comprising testosterone undecanoate solubilized in a carrier comprising at least one lipophilic surfactant and at least one hydrophilic surfactant
Data Source
AI summary
Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone undecanoate are provided.